Now showing items 1-3 of 3
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia
(International Society on Thrombosis and Haemostasis, 2012)
Background: BAY 86-6150 is a new human recombinant factor VIIa variant developed for high procoagulant activity and longer action in people with hemophilia with inhibitors. Objectives: To investigate the safety, ...
Clinical haematology training in South Africa
(Health and Medical Publishing Group, 2010)
Abstract not available